Recent Posts
Categories
Tag Archives: drugs
Tamiflu and cancer drugs lift Roche above forecasts
LONDON (Reuters) – A spike in U.S. demand for flu drug Tamiflu and strong sales of mainstay cancer medicines lifted first-quarter sales at Roche Holding AG by a bigger-than-expected 5 percent.
Top U.S. court to decide on deals to delay cheaper drugs
WASHINGTON (Reuters) – The U.S. Supreme Court will hear arguments on Monday over whether big drug companies can settle patent litigation with generic rivals by making deals to keep cheaper products off the market.
EU agency backs new MS drugs from Biogen and Sanofi
LONDON, March 22 – New multiple sclerosis drugs from Biogen Idec and Sanofi have been recommended for approval in Europe.
GlaxoSmithKline boss says new drugs can be cheaper
LONDON (Reuters) – The pharmaceutical industry should be able to charge less for new drugs in future by passing on efficiencies in research and development to its customers, according to the chief executive of GlaxoSmithKline Plc.
Insight: Cancer drugs proving worth earlier in testing
NEW YORK (Reuters) – Michael Weitz was out of options. The Californian had endured chemotherapy, radiation and surgery but his lung cancer still spread to his bones and brain.
FDA outlines path to test Alzheimer’s drugs earlier
CHICAGO (Reuters) – Proposed U.S. guidelines may make it easier for drug companies to test Alzheimer’s treatments in people at an earlier stage, when scientists think they may have the best shot at working.
Poor HIV patients improve with care beyond drugs: study
WASHINGTON (Reuters) – Patients stepping into Johns Hopkins University’s HIV clinic in east Baltimore do not just see a doctor or get prescriptions for their antiretroviral drugs. Many also get help finding a place to live or bus fare to … Continue reading
Ads lose balance when drugs become over-the-counter
NEW YORK (Reuters Health) – Consumer beware: When prescription drugs become available over-the-counter, advertisers start spotlighting the benefits and downplaying the risks, a new study finds.
Roche sees delayed threat from biosimilar drugs
ZURICH (Reuters) – Swiss drugmaker Roche Holding AG believes the threat from so-called biosimilar copies of its cancer drugs has been pushed back as companies developing the cut-price biotech medicines face development hurdles.